Results 21 to 30 of about 30,694,151 (287)
Striatal astrocytes act as a reservoir for L-DOPA.
L-DOPA is therapeutically efficacious in patients with Parkinson's disease (PD), although dopamine (DA) neurons are severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the uptake and ...
Masato Asanuma +4 more
doaj +1 more source
Metabolic engineering of Escherichia coli BL21 (DE3) for de novo production of l-DOPA from d-glucose
BackgroundProduction of l-tyrosine is gaining grounds as the market size of 3,4-dihydroxyphenyl-l-alanine (l-DOPA) is expected to increase due to increasing cases of Parkinson’s disease a neurodegenerative disease.
E. Fordjour +4 more
semanticscholar +1 more source
The therapeutic benefit of L-DOPA is commonly attributed to restoration of dopamine (DA) extracellular levels in the striatum of Parkinsonian patients. However, the loss of efficacy of L-DOPA after chronic use is paradoxically associated with a similar ...
Sylvia Navailles +3 more
doaj +1 more source
L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
L-3,4-dihydroxyphenylalanine (L-DOPA) has been successfully used in the treatment of Parkinson’s disease (PD) for more than 50 years. It fulfilled the criteria to cross the blood–brain barrier and counteract the biochemical defect of dopamine (DA).
A. Chagraoui +5 more
semanticscholar +1 more source
The pharmacological manipulation of neuroinflammation appears to be a promising strategy to alleviate l-DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD).
Patrick Pierre Michel (2019922) +5 more
core +1 more source
Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
Until now, the dopamine (DA) precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), remains the gold standard effective drug therapy for Parkinson’s disease (PD) patients.
Di-Sheng Lu +7 more
doaj +1 more source
L-DOPA functionalized, multi-branched gold nanoparticles as brain-targeted nano-vehicles.
The blood-brain barrier (BBB) is a protective endothelial barrier lining the brain microvasculature which prevents brain delivery of therapies against brain diseases.
Daniel Gonzalez-Carter +5 more
semanticscholar +1 more source
Summary The evolution of l‐DOPA 4,5‐dioxygenase activity, encoded by the gene DODA, was a key step in the origin of betalain biosynthesis in Caryophyllales.
Hester Sheehan +16 more
semanticscholar +1 more source
Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA).
Stefania eSgroi +3 more
doaj +1 more source
Evidence of
Background l-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime.
Wang Chun-Li +5 more
doaj +1 more source

